Sanofi (EPA:SAN) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened

Sanofi (EPA:SAN) shares passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of €76.23 and traded as low as €71.47. Sanofi shares last traded at €71.60, with a volume of 1,843,195 shares.

Key Sanofi News

Here are the key news stories impacting Sanofi this week:

• Positive Sentiment: Sanofi optioned its first development candidate from the Recursion Pharmaceuticals collaboration, triggering a $10 million milestone payment to Recursion and bringing total collaboration payments to $144 million. Sanofi will fund and lead development of the potential first-in-class oral immunology treatment, which is expected to enter Phase 1 trials in 2027. The deal supports Sanofi’s AI-enabled drug-discovery strategy and expands its early-stage inflammation pipeline. Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate
• Positive Sentiment: Sanofi and Canada’s pCPA signed a letter of intent covering Dupixent across four dermatology and respiratory indications. The agreement could support broader market access and future demand for Dupixent, one of Sanofi’s key growth products, although final terms and implementation remain pending. Sanofi and pCPA Sign Letter of Intent for Dupixent
• Neutral Sentiment: The European Commission closed an antitrust investigation into Sanofi’s marketing of competing flu vaccine Fluad without imposing a fine. Sanofi agreed to binding promotional and transparency commitments through 2030, reducing immediate financial risk but placing limits on how it discusses rival vaccines. Sanofi Must Set Record Straight on Rival Flu Shot Under EU Antitrust Deal
• Neutral Sentiment: New Australian study data provided additional insight into uptake of Sanofi’s RSV antibody nirsevimab. The update may help inform immunization strategies, but it did not announce a major change to the product’s regulatory or commercial outlook. Sanofi’s RSV Study in Queensland Offers Fresh Clues on Nirsevimab Uptake
• Negative Sentiment: Sanofi’s shares recently moved below their 200-day moving average, a technical signal that can reinforce cautious sentiment among momentum-focused investors. The regulatory settlement also keeps scrutiny on Sanofi’s vaccine marketing practices, despite the absence of a fine. Sanofi Stock Price Crosses Below 200-Day Moving Average

Sanofi Stock Up 1.5%

The stock’s 50 day moving average is €74.61 and its 200 day moving average is €76.10.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines.